Wet AMD 4 Symposium

Related

• 

  One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO

  Mark R. Barakat, MD

  Updates from the Field

  2020

• 

  2019 Winning Pitch Challenge Winner

  Updates from the Field

• 

  Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization

  Jeffrey L. Olson, MD

  Annual Meeting Talks

  2019